open access

Vol 21, No 3 (2016)
Original research articles
Published online: 2016-05-01
Submitted: 2015-04-01
Get Citation

Localized prostate cancer treated with external beam radiation therapy: Long-term outcomes at a European comprehensive cancer centre

Anna Boladeras, Evelyn Martinez, Ferran Ferrer, Cristina Gutierrez, Salvador Villa, Joan Pera, Ferran Guedea
DOI: 10.1016/j.rpor.2015.12.002
·
Rep Pract Oncol Radiother 2016;21(3):181-187.

open access

Vol 21, No 3 (2016)
Original research articles
Published online: 2016-05-01
Submitted: 2015-04-01

Abstract

Aims and background

To present survival and toxicity outcomes in patients with clinically localized, non-metastatic prostate cancer (PCa) treated with external beam radiotherapy (EBRT) combined with androgen deprivation therapy (ADT).

Materials and methods

Retrospective study of 849 PCa patients (pts) treated from 1996 to 2005. Until August 2000, all patients (281) were treated with conventional dose EBRT (<76[[ce:hsp sp="0.25"/]]Gy); subsequent pts received ≥76[[ce:hsp sp="0.25"/]]Gy (565 pts). Median age was 70 years (range, 39–82). Most pts were intermediate (353; 42.8%) or high-risk (344; 41.7%). Mean PSA was 10.1[[ce:hsp sp="0.25"/]]ng/ml. Median dose to the prostate was 75[[ce:hsp sp="0.25"/]]Gy. Complete ADT was administered to 525 pts (61.8%).

Results

Median follow-up was 109.6 months (range, 68.3–193.4). Overall survival (OS) was 92.5% and 81.1% at 5 and 10 years; by risk group (low, intermediate, high), 5- and 10-year OS rates were 94.3% and 85.9%, 92.3% and 79.2%, and 91.9% and 80.2% (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.728). Five- and 10-year BRFS was 94.1% and 80.6% (low risk), 86.4% and 70.9% (intermediate), and 85.2% and 71.4% (high) (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.0666). Toxicity included rectitis: grade 1 (G1) (277 pts; 32.6%), G2 (108; 12.7%), and G3 (20; 2.6%) and urethritis: G1 (294; 34.6%); G2 (223; 26.2%), and G3 (11; 1.3%). By dose rate (<76[[ce:hsp sp="0.25"/]]Gy vs. ≥76[[ce:hsp sp="0.25"/]]Gy), 5 and 10-year BRFS rates were 83.1% and 68.3% vs. 88.4% and 74.8% (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.038).

Conclusions

Our results are comparable to other published series in terms of disease control and toxicity. These findings confirm the need for dose escalation to achieve better biochemical control and the benefits of ADT in high-risk PCa patients.

Abstract

Aims and background

To present survival and toxicity outcomes in patients with clinically localized, non-metastatic prostate cancer (PCa) treated with external beam radiotherapy (EBRT) combined with androgen deprivation therapy (ADT).

Materials and methods

Retrospective study of 849 PCa patients (pts) treated from 1996 to 2005. Until August 2000, all patients (281) were treated with conventional dose EBRT (<76[[ce:hsp sp="0.25"/]]Gy); subsequent pts received ≥76[[ce:hsp sp="0.25"/]]Gy (565 pts). Median age was 70 years (range, 39–82). Most pts were intermediate (353; 42.8%) or high-risk (344; 41.7%). Mean PSA was 10.1[[ce:hsp sp="0.25"/]]ng/ml. Median dose to the prostate was 75[[ce:hsp sp="0.25"/]]Gy. Complete ADT was administered to 525 pts (61.8%).

Results

Median follow-up was 109.6 months (range, 68.3–193.4). Overall survival (OS) was 92.5% and 81.1% at 5 and 10 years; by risk group (low, intermediate, high), 5- and 10-year OS rates were 94.3% and 85.9%, 92.3% and 79.2%, and 91.9% and 80.2% (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.728). Five- and 10-year BRFS was 94.1% and 80.6% (low risk), 86.4% and 70.9% (intermediate), and 85.2% and 71.4% (high) (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.0666). Toxicity included rectitis: grade 1 (G1) (277 pts; 32.6%), G2 (108; 12.7%), and G3 (20; 2.6%) and urethritis: G1 (294; 34.6%); G2 (223; 26.2%), and G3 (11; 1.3%). By dose rate (<76[[ce:hsp sp="0.25"/]]Gy vs. ≥76[[ce:hsp sp="0.25"/]]Gy), 5 and 10-year BRFS rates were 83.1% and 68.3% vs. 88.4% and 74.8% (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.038).

Conclusions

Our results are comparable to other published series in terms of disease control and toxicity. These findings confirm the need for dose escalation to achieve better biochemical control and the benefits of ADT in high-risk PCa patients.

Get Citation

Keywords

Prostate cancer; High-dose; Toxicity; Radiation therapy; Survival rate

About this article
Title

Localized prostate cancer treated with external beam radiation therapy: Long-term outcomes at a European comprehensive cancer centre

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 21, No 3 (2016)

Pages

181-187

Published online

2016-05-01

DOI

10.1016/j.rpor.2015.12.002

Bibliographic record

Rep Pract Oncol Radiother 2016;21(3):181-187.

Keywords

Prostate cancer
High-dose
Toxicity
Radiation therapy
Survival rate

Authors

Anna Boladeras
Evelyn Martinez
Ferran Ferrer
Cristina Gutierrez
Salvador Villa
Joan Pera
Ferran Guedea

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl